10-K Decoder · All companies

Recursion Pharmaceuticals, Inc.

RXRX · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026

Open the dashboardInfographicSummary

FY2025 key figures

$FY2025FY2024Change
Revenue$74.7M$58.8M+26.9%
Operating income−$648M−$479M−35.3%
Net income−$645M−$464M−39.1%

Latest quarter: Q3 2026

Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 2, 2026

$Q3 2026Year earlierChange
Revenue$18.6M$5.20M+258%
Operating income−$123M−$172M+28.5%
Net income−$119M−$162M+26.7%

Q3 2026 dashboardQ3 2026 infographic

Questions

What was Recursion's revenue in FY2025?
$74.7M in FY2025 (Fiscal year ended Dec 31, 2025), +26.9% vs $58.8M a year earlier, per its 10-K filed Feb 2026.
Was Recursion profitable in FY2025?
No: net income was −$645M and operating income −$648M in FY2025.
What was Recursion's revenue in Q3 2026?
$18.6M (+258% vs a year earlier), per its Form 10-Q filed Nov 2, 2026.